The partners will use mass spec to look at markers in Barrett's patients who either progressed to more severe disease states or remained stable over a 10-year period.
The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
A proteogenomic analysis by a Moffitt Cancer Center-led team uncovered three subtypes of squamous cell lung cancer and treatment approaches to investigate.
